Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

Trial Success:
The KEYLYNK-001 study, a Phase III trial, evaluated the combination of Keytruda (pembrolizumab) and Lynparza (olaparib) in patients with advanced epithelial ovarian cancer. The trial met its primary endpoint of progression-free survival (PFS) but failed to meet the secondary endpoint of overall survival (OS)24.

Treatment Regimen:
Patients received Keytruda and chemotherapy for five cycles, followed by maintenance therapy with Keytruda and Lynparza, with or without bevacizumab, for up to nearly two years2.

Safety Profiles:
Both Keytruda and Lynparza showed safety profiles consistent with previous individual therapy studies2.

Clinical Significance:
The study highlights the potential of the Keytruda and Lynparza combination to improve outcomes for patients with ovarian cancer, particularly in terms of progression-free survival24.

Previous Failures:
This partial success comes after a series of failures for Keytruda in combination with Lynparza in other cancer types, such as non-small cell lung cancer (NSCLC)35.

Unmet Need:
The study addresses the ongoing need for new treatment options that can improve outcomes for patients with ovarian cancer2.

Sources:

2. https://www.clinicaltrialsarena.com/news/msd-ovarian-combo-trial/

3. https://www.biospace.com/merck-s-keytruda-continues-losing-streak-in-nsclc-with-phase-iii-flop

4. https://firstwordpharma.com/story/5919744

5. https://www.oncologypipeline.com/apexonco/keytrudalynparza-link-disappoints-again